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The Excess Burden of Cancer in Men in the UK
In general men are at significantly greater risk than 
women from nearly all of the common cancers that 
occur in both sexes (with the exception of breast 
cancer)	(White	2009,	Wilkins	2006,	DH	2007).	This	
report	will	consider	the	current	overall	burden	of	
cancer among men in the UK, estimated from the latest 
statistics, and outline the extent of the differences 
between the sexes. All figures and calculations 
reported	here	are	based	on	data	extracted	from	the	
Cancer	Research	UK	CancerStats	web	pages	extracted	
in	June	2009	(Cancer	Research	UK,	2009).
In	2006,	there	were	47,223	new	cancers	diagnosed	
in	men	(excluding	non-melanoma	skin	cancer)	and	
there was a very similar number of new cancers 
diagnosed	in	women	in	the	UK	(46,378).	However,	the	
corresponding	European	age-standardised	incidence	
rates	were	409.7	per	00,000	in	men	and	354.6	per	
100,000 in women; this difference is because of the 
generally longer life expectancy of women. 
Considering	deaths	from	cancer	in	the	UK,	the	most	
recent figures available, for 20072,	show	that	there	
were 80,907 in men and 74,557 in women accounting 
for 29% of total male mortality and 25% of total 
female mortality. As with the incidence figures, when 
translated	into	age-standardised	rates,	the	contrast	
between	men	and	women	is	more	profound,	with	
death	rates	of	2.3	per	00,000	in	males	and	53.	
per 100,000 in females. This difference results from 
a combination of different life expectancy and the 
increased	likelihood	of	men	having	more	fatal	cancers	
than	women.
The	male	age-standardised	incidence	rate	for	all	
cancers	combined	(excluding	non	melanoma	skin	
cancer)	in	Great	Britain	has	risen	from	353.7	per	
00,000	in	975	to	409.5	per	00,000	in	2006	even	
though the equivalent mortality rate (for the UK) has 
dropped	from	278.5	in	975	to	2.3	per	00,000	in	
20073. Similar figures for females are 264.5 in 1975 to 
354.9	per	00,000	in	2006	for	incidence;	and	72.7	in	
1975 to 153.1 per 100,000 in 2007 for mortality. These 
differences arise because, while the number of people 
developing cancer has increased, a combination of 
earlier diagnosis, improved diagnostic techniques and 
advances	in	care	and	treatment	has	resulted	in	more	
people	surviving	their	cancers.
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Figure 1: Top ten most common cancer cases for men, 
UK 2006
Figure 2: Top ten most common cancer deaths for men, 
UK 2007
1 2006 is the latest year for which incidence data are 
available	for	the	UK.
2 2007 is the latest year for which mortality data are 
available	for	the	UK.
3 Incidence data for the UK are only available from 1993 
onwards when the Northern Ireland Cancer Registry was 
set	up.	Thus,	trends	of	incidence	data	are	presented	for	
Great Britain for 1975 onwards. Mortality data for the UK 
are available for the whole time period.
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In terms of different types of cancer in men, although 
there are now substantially more cases of cancer of the 
prostate than any other form of the disease (see Fig. 
1), lung cancer is still the biggest contributor to male 
cancer death, accounting for 24% of the total (see Fig. 
2).	Prostate	cancer	makes	up	3%	of	the	total	deaths,	
with	colorectal	cancer	at	0%.	These	three	cancers	
make	up	53%	of	cancer	cases	and	47%	of	cancer	deaths	
in men and, understandably, have received most 
attention from policy makers; however, the cancers 
that	comprise	the	other	53%	of	deaths	in	men	should	
not	be	neglected.	
Male-specific cancers
With the introduction of Prostate Specific Antigen 
testing, alongside the increasingly ageing population, 
there	has	been	a	rapid	increase	in	the	incidence	of	
prostate	cancer,	with	rates	rising	from	32.5	per	00,000	
in	975	to	97.2	per	00,000	in	2006	in	Great	Britain.	
Whilst	the	death	rate	from	prostate	cancer	for	all	ages	
has risen since 1975, it is now gradually decreasing. 
However, this decline has predominately been 
influenced by trends in the over 85 year olds (see Fig. 3)	
and has, therefore, not affected the overall falling age-
standardised cancer mortality trend for all cancers.
Mortality from testicular cancer has continued to 
fall, but this is against a year on year increase in the 
incidence rate, which currently stands at 6.9 per 
100,000 men in the UK. Penile cancer is relatively very 
rare,	with	2	deaths	in	2007	across	the	UK,	with	88%	
of these occurring over the age of 50 years.
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Figure 3: Age-specific mortality rates, prostate cancer, UK, 1971–2007
Rate ratios of cancer deaths
Rate ratios of the mortality age-standardised rates for 
males	and	females	for	all	ages	and	truncated	into	two	
age	groups	are	presented	in	Table	.	All	were	found	to	
be statistically significant at the 95% confidence level. 
From the rate ratios of male to female deaths (see Fig. 
4	and	Table	,	excluding	the	577	non-melanoma	skin	
cancer	deaths	in	2007	across	both	sexes),	it	is	evident	
that there is a significantly higher rate of death for men 
(1.38) over all ages. This ratio is lower in the 15–64 age 
range (1.05) but rises substantially (to 1.57) over the 
age of 65 years. 
The mortality rate for lung cancer is substantially 
higher in men than women (see Fig. 5) due to differing 
smoking patterns over the previous 60 years, although 
the	gap	has	reduced	as	greater	numbers	of	men	have	
given up smoking relative to the numbers of females 
smokers (see Fig. 6). When rate ratios are calculated 
after excluding lung cancer to examine the influence on 
the burden of cancer in the two sexes after excluding 
the major cancer caused by smoking, then the ratio for 
all ages drops slightly to 1.31, with corresponding falls 
to 0.98 for 15-64 year olds and 1.51 for those aged 65 
and over. This could suggest that younger males have 
higher overall cancer mortality because of their excess 
rate	of	lung	cancer.	
If, however, rate ratios are calculated when breast 
cancer	and	those	cancers	which	are	unique	to	either	
men or women only are excluded, a different picture 
emerges, with 60% more men in the 15–64 year age 
range dying from cancers that should be affecting men 
and women equally. Thus a greater effect seems to be 
predominately because the cancer deaths that occur 
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Table 1: Rate* ratio of male to female cancer mortality, UK 2007
ICD-10 code Site description 
Mortality rate ratios
All ages 15–64 65+
C00-C97	excl.	C44 All	cancers	ex.	NMSC .38 .05 .57
C00-C97	excl.	C44	and	C33-C34 All	cancers	ex.	NMSC	and	lung	cancer .3 0.98 .5
C00-C97	excluding	C44,	C50,	C5-
C58,	C60-C63
All cancers ex. NMSC, breast and sex-specific .69 .60 .73
C00-C97	excluding	C44,	C33-C34,	
C50,	C5-C58,	C60-C63
All	cancers	ex.	NMSC,	breast,	lung	and	sex-
specific
.7 .69 .72
C5 Oesophagus 2.68 3.63 2.33
C6 Stomach 2.32 .92 2.46
C8-	C2 Colorectum	and	anus .56 .48 .59
C22 Liver .99 2.20 .90
C25 Pancreas .27 .44 .20
C33-C34 Lung .65 .38 .78
C43 Malignant	melanoma	of	skin .46 .40 .53
C64-C66	&	C68 Kidney, other and unspecified urinary organs 2.07 2.8 2.03
C67 Bladder 2.94 2.34 3.08
C70-C72 Brain	and	CNS .52 .56 .54
C82-C85	&	C96 Non-Hodgkin’s lymphoma .57 .64 .54
C90 Multiple myeloma .39 .24 .44
C9-C95 Leukaemia .79 .57 .9
* European age-standardised rates.
All of the above mortality rate ratios were statistically significant at the 95% confidence level.
Figure 4: Rate* ra�o of male to female cancer mortality, UK 2007 
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* See Table 1 for complete cancer site label descrip�ons.
All of the above mortality rate ra�os were sta�s�cally signiﬁcant at the 95% conﬁdence level.
Cancer site
in younger women are those related to the breast 
and	genital	organs	(37.%	overall	of	cancer	deaths	in	
those aged 15–64; and around 50% in the 35–44 years 
age group; Table 2). For men there are no significant 
numbers of deaths that can be attributed to a sex-
specific cause in these early years (only 4.7% deaths in 
ages 15–64 are for male-specific cancers). 
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Table 2: Total n�mber�� of �eat��� from all cancer�� e�cl��in�� brea��t cancer, t�e ��e�����eci��c cancer�� an� non�melanoma ���in                
cancer; an� t�e �ercenta��e�� of t�e��e o�t of t�e n�mber�� of �eat��� from all cancer�� e�cl��in�� non�melanoma ���in cancer, by 
a��e ��ro��, UK 2007
Under 1 to 14 years 15–64 years 35–44 years 65+ years   All ages
Male 58	(00%) 7,659	(95.3%) ,77	(99.8%) 52,246	(84.4%) 70,063	(87.0%)
Female 6	(98.3%) ,363	(62.9%) 856	(49.9%) 43,484	(77.4%) 54,963	(73.9%)
Figure 5: European age-standardised mortality rates, lung cancer, by sex, UK, 1971–2007
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Figure 6: Percentage of men and women aged 16 and over, who smoke cigare�es, Great Britain, 1948–2007
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Source: General Household Survey, Oﬃce for Na�onal Sta�s�cs
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Table 3: Rate* ratio of male to female cancer inci�ence, UK 2006 
ICD-10 code Site description Incidence rate ratios
All ages 15–64 65+
C00-C97	excl.	C44 All	cancers	ex.	NMSC .6 0.80 .57
C00-C97 excl. C44 and C33–C34 All	cancers	ex.	NMSC	and	lung	cancer .0 0.76 .53
C00-C97	excluding	C44,	C50,	
C5-C58,	C60-C63
All	cancers	ex.	NMSC,	breast	and	sex	
specific
.62 .44 .77
C00-C97 excluding C44, C33–
C34,	C50,	C5-C58,	C60-C63
All	cancers	ex.	NMSC,	breast,	lung	and	sex	
specific
.6 .45 .77
C5 Oesophagus 2.48 3.0 2.22
C6 Stomach 2.48 2.44 2.50
C18–C21 Colorectum	and	anus .54 .40 .62
C22 Liver 2.2 2.35 2.8
C25 Pancreas .27 .38 .2
C33-C34 Lung .64 .37 .80
C43 Malignant	melanoma	of	skin 0.92 0.76 .42
C64–C66 & C68 Kidney, other and unspecified urinary 
organs
.99 2.0 2.05
C67 Bladder 3.30 2.75 3.54
C70–C72 Brain	and	CNS .53 .58 .52
C82–C85 & C96 Non-Hodgkin’s lymphoma .39 .36 .40
C90 Multiple myeloma .52 .54 .52
C91–C95 Leukaemia .72 .56 .99
* European age-standardised rates.
All of the above incidence rate ratios were statistically significant at the 95% confidence level.
Figure 7: Rate* ra�o of male to female cancer incidence, UK 2006 
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* See Table 3 for complete cancer site label descrip�ons. 
All of the above incidence rate ra�os were sta�s�cally signiﬁcant at the 95% conﬁdence level.
Cancer site
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Box 1: Factors involved in the 
development of cancer in men
• Lifestyle  
(Martin-Moreno et al. 2008, White 2009)
• Genetics  
(White 2009)
• Knowledge of genetic links within families 
(Moynihan & Huddart 2009) 
• Reduced uptake of available screening 
(Brenner, H et al. 2007).
• Humoral and cellular immunity  
(Bouman et al. 2004)
• Help seeking behaviour  
(Smith et al 2005, Branney 2008)
• Knowledge of cancer  
(Macdonald et al. 2004)
The increased risk in mortality rates for males 
compared	with	females	is	seen	across	a	broad	range	of	
cancer	sites	(Table	).
Rate ratios of cancer incidence
When incidence rate ratios are considered (see Fig. 7 
and	Table	3),	it	can	be	seen	that	there	are	more	women	
registered with cancer in the UK in the 15–64 year 
age group (male to female rate ratio = 0.80) but again 
when breast cancer and the sex-specific cancers for 
both	men	and	women	are	excluded,	a	greater	number	
of men are seen to be at risk of the non sex-specific 
cancers (ratio = 1.44). This significant excess is seen 
across the cancers listed in Table 3, with the exception 
of	malignant	melanoma,	where	more	women	are	
diagnosed	although	(as	can	be	seen	from	Table	)	
more	men	die	from	this	form	of	cancer.	All	incidence	
rate ratios were statistically significant at the 95% 
confidence level.
Conclusion
The explanations as to why men seem to be so much 
more at risk of so many cancers are complex and still 
only partially understood. Clearly the incidence of 
those cancers influenced by smoking, such as cancers 
of the lung and bladder, and those caused by excessive 
alcohol consumption will reflect sex differences in such 
behaviours. However, there are likely to be a number 
of other factors that may be associated including other 
risk factors and potential differences in symptom 
awareness and the propensity to seek early medical 
advice (see box 1). Due to the uncertainty as how all 
these factors impact on sex differences in cancer risk, 
more	extensive	research	in	this	area	is	required.
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